Despite the proven health benefits of weight loss medications like Wegovy and Zepbound in preventing serious health issues like heart attacks and strokes, the financial case for their widespread adoption remains unclear. A recent study from the University of Chicago indicates that for these medications to be deemed cost effective, their prices would need significant reductions: Wegovy’s cost would need to drop by over 80% while Zepbound would need about a one-third reduction. The long-term financial benefits of improved health outcomes are uncertain.
To be considered cost effective by a common measure used by health economists, the price of Novo Nordisk's Wegovy would need to be cut by over 80 percent, to $127 per month.
Eli Lilly's Zepbound would be cost effective only if its price fell by nearly a third, to $361 per month, because it produced greater benefits in clinical trials.
Collection
[
|
...
]